These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36053757)

  • 1. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population.
    Tanaka Y; Okuda K; Takeuchi Y; Katayama K; Haji Y; Yamanishi Y; Tribanek M; Guimbal-Schmolck C; Takeuchi T
    Mod Rheumatol; 2023 Jul; 33(4):680-689. PubMed ID: 36053757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.
    Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D;
    Ann Rheum Dis; 2012 Jun; 71(6):817-24. PubMed ID: 22121129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Yishen Tongbi decoction versus methotrexate in patients with active rheumatoid arthritis: A double-blind, randomized, controlled, non-inferiority trial.
    Xu J; Zhang L; Xu Y; Yu J; Zhao L; Deng H; Li M; Zhang M; Lei X; Hu C; Jiao W; Dai Z; Liu L; Chen G
    Phytomedicine; 2023 Apr; 112():154704. PubMed ID: 36796186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
    Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
    Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
    Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate.
    Fan W; Zhao DB; Hu SX; Xu HJ; Zhang X; Zhang MJ; Chen ZW; Zhang FX; Zhu P; Li XF; Bi LQ; Zhou B; Bao CD
    Rheumatol Int; 2014 Nov; 34(11):1519-27. PubMed ID: 24671501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
    J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Smolen JS; Feist E; Fatenejad S; Grishin SA; Korneva EV; Nasonov EL; Samsonov MY; Fleischmann RM;
    N Engl J Med; 2022 Aug; 387(8):715-726. PubMed ID: 36001712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
    Nasonov E; Fatenejad S; Feist E; Ivanova M; Korneva E; Krechikova DG; Maslyanskiy AL; Samsonov M; Stoilov R; Zonova EV; Genovese M
    Ann Rheum Dis; 2022 Apr; 81(4):469-479. PubMed ID: 34344706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
    Combe B; Furst DE; Keystone EC; van der Heijde D; Luijtens K; Ionescu L; Goel N; Emery P
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):299-307. PubMed ID: 26238672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.